09.01.2020 • NewsElaine BurridgeAstellas

Astellas Acquires Xyphos Biosciences

Astellas Acquires Xyphos Biosciences (c) Xyphos Biosciences
Astellas Acquires Xyphos Biosciences (c) Xyphos Biosciences

Japanese drugmaker Astellas Pharma has boosted its immuno-oncology capabilities with the purchase of US-based Xyphos Biosciences. The acquisition was the second last month for the Tokyo-based pharma, which had also agreed to buy US gene therapy company Audentes Therapeutics for $3 billion.

The deal, which is worth up to $665 million, gives Astellas access to Xyphos’s novel ACCEL (Advanced Celllular Control through Engineered Ligands) technology platform. 

“Combining this technology with our capabilities in cell therapy that we have been working on so far, we can create next-generation high-function cells and maximize the value of our technology,” said Astellas president and CEO Kenji Yasukawa.

Xyphos’s proprietary molecules can be delivered to natural immune cells or to engineered Chimeric Antigen Receptor (CAR) cells to generate immunotherapies for oncology.   Xyphos’ first CAR-T cell product candidate is in preclinical development and scheduled to be tested in a first-in-human clinical study in 2021.

Astellas paid $120 million upfront and will pay the rest on future development milestones being met.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read